Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation

Blood

Volumn 92, Issue 5, 1998, Pages 1661-1667

  Nilsson, Bo ^b   Larsson, Rolf ^b   Hong, Jaan ^b   Elgue, Graciela ^b   Nilsson Ekdahl, Krístína ^b   Sahu, Arvind ^b   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPSTATIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOPULMONARY BYPASS; CELL ACTIVATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENZYME IMMUNOASSAY; EXTRACORPOREAL CIRCULATION; HUMAN; IMMUNOCHEMISTRY; NEUTROPHIL; PRIORITY JOURNAL;

EID: 0032170593     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.5.1661.417k34_1661_1667     Document Type: Article

References (38)

1. Greeley WJ, Ungerleider RM: Assessing the effect of cardiopulmonary bypass on the brain. Ann Thorac Surg 52:417, 1991
2. Kirklin JK: The postperfusion syndrome: Inflammation and the damaging effects of cardiopulmonary bypass, in Tinker JH (ed): Cardiopulmonary Bypass: Current Concepts and Controversies. Philadelphia, PA, Saunders, 1989, p 131
3. Oeveren Wv, Kazatchkine MD, Descamps-Latscha B, Haillet F, Fischer E, Carpemier A, Wildevuur CRH: Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 89:888, 1985
4. Westaby S: Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by extracorporeal circuit. Intensive Care Med 13:89, 1987
5. Gillinov AM, DeValeria PA, Winkelstein JA, Wilson I, Shaw D, Yeh CG, Rudolph AR, Baumgartner WA, Herskowitz A, Cameron DE: Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann Thorac Surg 55:619, 1993
6. Sims PJ, Wiedmer T: The response of human platelets to activated components of the complement system. Immunol Today 12:338, 1991
7. Johnson RJ: Complement activation by biomaterials. Prog Clin Biol Res 337:507, 1991
8. Pekna M, Nilsson L, Nilsson Ekdahl K, Nilsson UR, Nilsson B: Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin Exp fmmunol 91:404, 1993
9. Wachtfogel YT, Harpel PC, Edmunds LHJ, Colman RW: Formation of C1s-C1-inhibitor, kallikreyi-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood 73:468, 1989
10. Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith JS, Tracey JB, Malis LA, Squinto SP, Rolling SA: Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 96:1564, 1995
11. Mulligan MS, Yeh CG, Rudolph AR, Ward PA: Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury. J Immunol 148:1479, 1992
12. Ino Y, Suzuki S, Iwaki M, Yoshikawa T: Inhibitory effects of FUT-175, a new synthetic protease inhibitor, on intravascular hemolysis by human serum in mice. Int J Immunopharmacol 9:533, 1987
13. Sundaram S, Gikakis N, Hack CE, Niewiarowski S, Edmunds LH, Rao AK, Sun L, Cooper SL, Colman RW: Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost 75:76, 1996
14. Sahu A, Kay BK, Lambris JD: Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol 157:884, 1996
15. Morikis D, Assa,Munt N, Sahu A, Lambris LD: Solution structure of Compstatin, a potent complement inhibitor. Protein Sci 7:619, 1998
16. Moore WT: Integration of mass spectrometry into strategies for peptide synthesis. Biol Mass Spectrom 22:149, 1993
17. Angefetti RH, Bibbs L, Bonewald LF, Fields GB, McMurrey JS, Moore WT, Stults JT: Techniques in protein chemistry VII, in Marshak DR (ed): Formation of Disulfide Bond in an Octreotide-Like Peptide. San Diego, CA, Academic Press, 1996, p 261
18. Hammer CH, Wirtz GH, Renter L, Gresham HD, Tack BF: Large scale isolation of functionally active components of the human complement system. J Biol Chem 256:3995, 1981
19. Lambris JD, Müller-Eberhard HJ: Isolation and characterization of a 33,000-Dalton fragment of complement factor B with catalytic and C3b binding activity. J Biol Chem 259:12685, 1984
20. Catana E, Schifferli JA: Purification of human complement factor D from the peritoneal fluid of patients on chronic ambulatory peritoneal dialysis. J Immunol Methods 138:265, 1991
21. Bokisch VA, Müller-Eberhard HJ, Cochrane CG: Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med 129:1109, 1969
22. Fishelson Z, Pangburn MK, Müller-Eberhard HJ: C3 convertase of the alternative complement pathway: Demonstration of an active, stable C3b,Bb(Ni) complex. J Biol Chem 258:7411, 1983
23. Gong J, Larsson R, Nilsson Ekdahl K, Mollnes TE, Nilsson UR, Nilsson B: Tubing loops as a model for cardiopulmonary bypass circuits: Both the biomaterial and the blood-gas interfaces induce complement activation in an in vitro model. J Clin Immunol 16:223, 1996
24. Larsson R, Elgue G, Larsson A, Nilsson Ekdahl K, Nilsson UR, Nilsson B: Inhibition of complement activation by soluble recombinant CRI under conditions resembling those in a cardiopuimonary circuit: Reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial. Immunopharmacology 38:119, 1997
25. Nilsson Ekdahl K, Nilsson B, Pekna M, Nilsson UR: Generation of iC3 on the interphase between blood and gas. Scand J Immunol 35:85, 1992
26. Mayer MM: Complement and complement fixation, in Kabat EA, Mayer MM (ed): Experimental Immunochemistry. Springfield, IL, Thomas, 1961, p 133
27. Mollnes T, Lea T, Frøland SS, Harboe M: Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against neoantigen on the complex. Scand J Immunol 22:703, 1985
28. Nilsson UR, Storm KE, Nilsson B, Sjölin-Forsberg G, Hällgren R: Hereditary dysfunction of the third component of complement associated with an SLE-like syndrom and meningococcal meningitis. Arthritis Rheum 35:580, 1992
29. Nilsson B, Nilsson UR, Karlsson-Panra A, Sjölin-Forsberg G, Hällgren R: Reconstitution of the alternative pathway of complement by plasma infusions given to a patient with an SLE-like syndrome associated with a hereditary C3 dysfunction. Ann Rheum Dis 53:691, 1994
30. Kazatchkine MD, Carreno MP: Activation of the complement system at the interface between blood and artificial surfaces. Biomaterials 9:30, 1988
31. Chenoweth DE: Complement activation produced by biomaterials. Trans Am Soc Artif Organs 32: 226, 1986
32. Nilsson L, Storm KE, Thelin S, Bagge L, Hultman J, Thorelius J, Nilsson U: Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. Artif Organs 14:46, 1990
33. Videm V, Svennevig JL, Fosse E, Semb G, Østerud A, Mollnes TE: Reduced complement activation with heparin-coated oxygenators and tubings in coronary bypass surgery. J Thorac Cardiovasc Surg 113:806, 1992
34. Mollnes TE, Videm V, Götze O, Harboe M, Oppermann M: Formation of C5a during cardiopulmonary bypass: Inhibition by precoating with heparin. Ann Thorac Surg 52:92, 1991
35. Fearon T: Anti-inflammatory and immunosuppresive effects of recombinant soluble complement receptors. Clin Exp Immunol 86:43, 1991 (suppl 1)
36. Morgan BP: Complement regulatory molecules: Application to therapy and transplantation. Immunol Today 16:257, 1995
37. Kirschfink M, Knoblauch K, Roelcke D: Activation of complement by cold agglutinins. Infusionsther Transfusionsmed 21:405, 1994
38. Rosse WF: Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine 76:63, 1997